Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential future dermatological indications for tacrolimus ointment.

Thomas Ruzicka1, Till Assmann, Mark Lebwohl

  • 1Department of Dermatology, University of Düsseldorf, Moorenstr 5, 40225 Düsseldorf, Germsny.

European Journal of Dermatology : EJD
|September 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis.

International journal of dermatology·2026
Same author

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2026

Tacrolimus ointment, a steroid-free treatment for atopic dermatitis, shows promise for other inflammatory skin conditions. This review explores its efficacy beyond its approved use.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis is a chronic inflammatory skin disease.
  • Tacrolimus ointment is a steroid-free topical immunomodulator approved for atopic dermatitis.
  • It works by inhibiting T-cell activation and cytokine production.

Purpose of the Study:

  • To review the evidence for tacrolimus ointment's use in various inflammatory skin disorders.
  • To explore its potential in conditions difficult to manage with standard therapies.

Main Methods:

  • Review of clinical trials and publications on tacrolimus ointment.
  • Focus on dermatological disorders beyond atopic dermatitis.

Main Results:

  • Tacrolimus ointment is effective and well-tolerated for atopic dermatitis.

Related Experiment Videos

  • Evidence suggests efficacy in psoriasis, lichen planus, pyoderma gangrenosum, lichen sclerosus, contact dermatitis, rheumatoid arthritis leg ulcers, steroid-induced rosacea, and alopecia areata.

    • Conclusions:

    • Tacrolimus ointment is a valuable therapeutic option for atopic dermatitis.
    • Further research and clinical studies are recommended for its off-label uses in other inflammatory skin conditions.